Skip to main content
ACTU
NASDAQ Life Sciences

Actuate Therapeutics Appoints Oncology Veteran Dr. Martin Huber to Board Amidst Going Concern

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.01
Mkt Cap
$68.577M
52W Low
$1.58
52W High
$11.99
52W Position info
91% above low
Off High info
75% below high
Rel. Volume
Market data snapshot near publication time

ACTU sits 91% above its 52-week low of $1.58.

Summary

Actuate Therapeutics appointed Dr. Martin H. Huber, a seasoned oncology drug development expert, to its Board of Directors, a strategic move to bolster leadership as the company navigates a "going concern" warning.


Key Events · Executive and Board Changes · ACTU

  • New Director Appointment

    Dr. Martin H. Huber, MD, was appointed to the Board of Directors, expanding the board from seven to eight members, effective May 1, 2026.

  • Strengthens Oncology Expertise

    Dr. Huber brings decades of experience in oncology drug development, regulatory strategy, and commercialization from leadership roles at Mersana Therapeutics, Xilio Therapeutics, and TESARO, having contributed to the approval of multiple oncology medicines.

  • Strategic Move Amidst Financial Concerns

    This appointment comes as the company faces a "going concern" warning, with cash expected to last only until July 2026, signaling an effort to enhance strategic guidance for its clinical programs.

  • Compensation Details

    Dr. Huber will receive an initial grant of 30,000 non-statutory stock options, an annual retainer of $44,000, and a quarterly consulting fee of $3,000 for R&D advisory services.


Analysis · ACTU · Life Sciences

Actuate Therapeutics, a clinical-stage biopharmaceutical company facing a "going concern" warning, has strategically appointed Dr. Martin H. Huber to its Board of Directors. Dr. Huber brings extensive experience in oncology drug development, regulatory strategy, and commercialization, having held senior leadership roles at Mersana Therapeutics, Xilio Therapeutics, and TESARO, and contributing to the approval of multiple oncology medicines. This appointment, which expands the board from seven to eight directors, is a notable move to strengthen the company's leadership and strategic capabilities as it works to advance its lead drug, elraglusib, and address its near-term financial challenges. Investors should monitor how this expertise translates into progress on clinical programs and future financing efforts.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACTU was trading at $3.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.6M. The 52-week trading range was $1.58 to $11.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACTU - Latest Insights

ACTU
Nov 13, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.2853
Real-time Price: $0.2361 info
Change: -$0.0492 (-17%) info
Market Cap: $14.83M info
ACTU
Nov 13, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.2853
Real-time Price: $0.2361 info
Change: -$0.0492 (-17%) info
Market Cap: $14.83M info
ACTU
Oct 30, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3351
Real-time Price: $0.2361 info
Change: -$0.099 (-30%) info
Market Cap: $14.83M info
ACTU
Oct 28, 2026, 5:17 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3833
Real-time Price: $0.2361 info
Change: -$0.1472 (-38%) info
Market Cap: $14.83M info
ACTU
Oct 28, 2026, 8:00 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.370
Real-time Price: $0.2361 info
Change: -$0.1339 (-36%) info
Market Cap: $14.83M info